XTX Topco Ltd Takes Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

XTX Topco Ltd bought a new stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 31,375 shares of the company’s stock, valued at approximately $178,000. XTX Topco Ltd owned about 0.06% of Voyager Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the business. Barclays PLC grew its stake in Voyager Therapeutics by 9.9% in the fourth quarter. Barclays PLC now owns 114,790 shares of the company’s stock worth $650,000 after purchasing an additional 10,328 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Voyager Therapeutics in the 4th quarter worth $746,000. Legal & General Group Plc lifted its holdings in shares of Voyager Therapeutics by 65.2% in the 4th quarter. Legal & General Group Plc now owns 19,245 shares of the company’s stock worth $109,000 after buying an additional 7,597 shares during the period. ADAR1 Capital Management LLC lifted its holdings in shares of Voyager Therapeutics by 212.0% in the 4th quarter. ADAR1 Capital Management LLC now owns 126,792 shares of the company’s stock worth $719,000 after buying an additional 86,158 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Voyager Therapeutics in the 4th quarter worth $267,000. Institutional investors own 48.03% of the company’s stock.

Insider Transactions at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of the company’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total transaction of $37,335.55. Following the completion of the sale, the chief executive officer now owns 430,931 shares of the company’s stock, valued at $1,478,093.33. This represents a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.53% of the company’s stock.

Wall Street Analysts Forecast Growth

VYGR has been the subject of several research reports. Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price objective on Voyager Therapeutics and gave the stock an “overweight” rating in a research note on Wednesday, March 12th. Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Canaccord Genuity Group decreased their price objective on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, March 13th. Finally, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $13.97.

Voyager Therapeutics Trading Up 1.7 %

Shares of VYGR stock opened at $3.53 on Tuesday. The company has a market capitalization of $195.25 million, a P/E ratio of 4.97 and a beta of 1.02. The business’s 50 day moving average is $3.63 and its two-hundred day moving average is $5.15. Voyager Therapeutics, Inc. has a 12-month low of $2.75 and a 12-month high of $9.55.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.24). The firm had revenue of $4.39 million for the quarter, compared to analysts’ expectations of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same quarter in the previous year, the firm posted $1.25 earnings per share. On average, research analysts predict that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.